Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacPROTACs
- Development stage
- Preclinical
- Lead developer
- Foundation for Neglected Disease Research
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
bacPROTACs (specifically Homo-BacPROTACs) are a novel class of small molecule degraders being developed by the Foundation for Neglected Disease Research (FNDR) for the treatment of tuberculosis, including multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains. These molecules utilize the Bacterial Proteolysis-Targeting Chimera (bacPROTAC) technology to induce the degradation of ClpC1, an essential ATPase that serves as a chaperone for the ClpP protease complex in *Mycobacterium tuberculosis*. By hijacking the bacteria's own proteolytic machinery, bacPROTACs cause the selective degradation of ClpC1, leading to proteotoxic stress and bacterial cell death. This degradation-based approach offers a distinct advantage over traditional inhibition by potentially overcoming resistance mechanisms and providing more sustained therapeutic effects. The program is currently in the preclinical hit-to-lead stage.
- Other names
- Homo-BacPROTACsClpC1 degradersClpC-1 degradersClpC 1 degradersBacPROTACs
02
Targets
ClpC1 (Bacterial ClpC1)ClpC2 (ATP-dependent protease ATP-binding subunit ClpC2)
Beyond the preview
Go deeper on bacPROTACs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacPROTACs.